EP1476554A1 - Nouveau compose pour l'inhibition de serine-proteinases et pour l'inhibition d'infections virales ou de propagation virale : rld 8564 - Google Patents

Nouveau compose pour l'inhibition de serine-proteinases et pour l'inhibition d'infections virales ou de propagation virale : rld 8564

Info

Publication number
EP1476554A1
EP1476554A1 EP03742557A EP03742557A EP1476554A1 EP 1476554 A1 EP1476554 A1 EP 1476554A1 EP 03742557 A EP03742557 A EP 03742557A EP 03742557 A EP03742557 A EP 03742557A EP 1476554 A1 EP1476554 A1 EP 1476554A1
Authority
EP
European Patent Office
Prior art keywords
peptide
rld
fragments
analogs
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03742557A
Other languages
German (de)
English (en)
Inventor
Wolf-Georg Forssmann
Frank Kirchhoff
Jan MÜNCH
Peter Kreutzmann
Hans-Jürgen MÄGERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IPF Pharmaceuticals GmbH
Original Assignee
IPF Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IPF Pharmaceuticals GmbH filed Critical IPF Pharmaceuticals GmbH
Priority to EP03742557A priority Critical patent/EP1476554A1/fr
Publication of EP1476554A1 publication Critical patent/EP1476554A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a polypeptide (protein) with serine proteinase-inhibitory, in particular plasmin and elastase-inhibitory properties and inhibitory properties against viruses: RLD 8564 (recombinant 15th LEKTI domain).
  • the invention further comprises fragments and / or derivatives derived from the RLD 8564 and the combination of these peptide active ingredients.
  • a drug containing the natural, recombinant and synthetic peptides for use in medical indications and for use as a diagnostic agent.
  • RLD 8564 the 15th domain of the serine proteinase inhibitor LEKTI, was heterologously expressed and purified in E. coli using conventional RT-PCR and standard cloning methods.
  • the recombinant peptide obtained has the following amino acid sequence in the one-letter code:
  • RLD 8564 consists of 78 amino acids and has a molecular mass of 8564 Da.
  • the six cysteines are preferably bridged according to the Kazal type (1-5, 2-4, 3-6) known for inhibitors.
  • Serine proteinase inhibitors have been extensively described in their structure at the protein and DNA sequence level and in their biological function (for a review see: Roberts, RM et al. (1995), Crit. Rev. Eukaryot. Gene Expr., 5 ( 3-4): 385-436). Fragments, analogs and / or derivatives of RLD 8564 are substances with biological properties comparable to those of RLD 8564, which can be structurally derived from the sequence of RLD 8564. Derived structures are, in particular, those that
  • N-terminal are shortened by 1, 2 or 3 amino acids
  • C-terminal are shortened by 1, 2 or 3 amino acids
  • Derived peptides can also exhibit several of these changes.
  • Comparable properties mean at least 50% of the inhibition properties on plasmin and elastase according to the test methods described here, ie at most twice the IC 50 value.
  • the IC 50 (inhibitory concentration 50%) was 9xl0 "7 M.
  • the data generated in this way show (FIGS. 1 and 2) that the peptide RLD 8564, which corresponds to the 15th LEKTI domain, is not only capable of the serine proteinase trypsin (Magert, HJ. Et al, (2002) Int. J. Biochem. Cell Biol, 34 (6), 573-576), but surprisingly also inhibit human plasmin and human leukocyte elastase. RLD 8564 can therefore protect against the proteolytic activity of these enzymes.
  • Plasmin is a serine proteinase that plays an important role in inflammatory processes, but especially in fibrinolysis.
  • regulation of the proteolytic activity of plasmin by inhibitors is of great physiological importance. This regulation has clinical relevance, for example, in the case of transplants, burns, disorders of the blood coagulation system (fibrinolysis) or liver diseases.
  • Elastase has a crucial role in the controlled breakdown of functionally damaged connective tissue (JANOFF, 1985) and thus has important biological functions. Their proteolytic activity must be carefully controlled, as otherwise the enzyme may have pathological attacks on structural proteins in its own organism. An example of a pathological effect that develops due to a disturbance in the balance between proteinase (leukocyte elastase) and its specific inhibitor is pulmonary emphysema. Proteinases can also be released from invaded microorganisms. All these enzymes are able to proteolytically decompose tissues and proteins of the organism and thus also represent an objective danger for the individual concerned. For this reason, a targeted control of the proteinases is necessary.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne le peptide RLD 8564 ayant la séquence aminoacide suivante : GPDSEMCKDYRVLPRIGYLCPKDLKPVCGDDGQTYNNPCMLCHENLIRQTNTHIRSTGKCEESSTPGTTAASMPPSDE.
EP03742557A 2002-02-22 2003-02-20 Nouveau compose pour l'inhibition de serine-proteinases et pour l'inhibition d'infections virales ou de propagation virale : rld 8564 Withdrawn EP1476554A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP03742557A EP1476554A1 (fr) 2002-02-22 2003-02-20 Nouveau compose pour l'inhibition de serine-proteinases et pour l'inhibition d'infections virales ou de propagation virale : rld 8564

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
DE10207602 2002-02-22
DE10207602 2002-02-22
DE10208302 2002-02-26
DE10208302 2002-02-26
DE10209307 2002-03-02
DE10209307 2002-03-02
DE10220802 2002-05-10
DE10220802 2002-05-10
EP02015418 2002-07-11
EP02015418 2002-07-11
PCT/EP2003/001704 WO2003070953A1 (fr) 2002-02-22 2003-02-20 Nouveau compose pour l'inhibition de serine-proteinases et pour l'inhibition d'infections virales ou de propagation virale : rld 8564
EP03742557A EP1476554A1 (fr) 2002-02-22 2003-02-20 Nouveau compose pour l'inhibition de serine-proteinases et pour l'inhibition d'infections virales ou de propagation virale : rld 8564

Publications (1)

Publication Number Publication Date
EP1476554A1 true EP1476554A1 (fr) 2004-11-17

Family

ID=27761588

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03742557A Withdrawn EP1476554A1 (fr) 2002-02-22 2003-02-20 Nouveau compose pour l'inhibition de serine-proteinases et pour l'inhibition d'infections virales ou de propagation virale : rld 8564

Country Status (3)

Country Link
EP (1) EP1476554A1 (fr)
AU (1) AU2003210317A1 (fr)
WO (1) WO2003070953A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009010942A1 (de) 2009-02-27 2010-09-02 Universitätsklinikum Schleswig-Holstein Serinprotease-Inhibitoren zur spezifischen Inhibition von Gewebs-Kallikreinen
CA3179244A1 (fr) 2020-03-31 2021-10-07 Pharis Biotec Gmbh Polypeptide pour la prophylaxie et le traitement d'infections virales

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939851B1 (en) * 1999-06-22 2005-09-06 Pharis Biotec Gmbh Serine proteinase inhibitors
EP1294768A1 (fr) * 2000-03-02 2003-03-26 Isis Innovation Limited Mutations dans spink5 responsables du syndrome de netherton et de maladies atopiques
WO2002066513A2 (fr) * 2001-02-19 2002-08-29 Ipf Pharmaceuticals Gmbh Fragments humains de lekti circulants hf7072, hf7638 et hf14448 ainsi que leur utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03070953A1 *

Also Published As

Publication number Publication date
WO2003070953A1 (fr) 2003-08-28
AU2003210317A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
DE3785615T2 (de) Hemmungsstoffe der serin-protease.
EP0209061B1 (fr) Peptides à activité anticoagulante, leur procédé de préparation, d'obtention, leur application et les agents les contenant
CN101297033B (zh) 由菠萝蛋白酶获得的清创组合物及其制备方法
EP0134479B1 (fr) Inhibiteurs de la protéinase modifiés, procédés pour leur préparation et compositions pharmaceutiques les contenant
US5612194A (en) Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
DE69633623T2 (de) Cystein-Protease-Inhibitoren für die Behandlung von allergischen Krankheiten verursacht duch IgE
US6057297A (en) Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof
CA2053242C (fr) Inhibiteur de la protease
US5846755A (en) Method for determining the therapeutic activity of metalloproteinase inhibitor compounds
WO1992020362A1 (fr) Peptides favorisant le developpement de cellules nerveuses et leurs utilisations
WO1995030432A1 (fr) Utilisation de proteoglycannes de sulfate de chondroitine pour la protection des neurones
EP1476554A1 (fr) Nouveau compose pour l'inhibition de serine-proteinases et pour l'inhibition d'infections virales ou de propagation virale : rld 8564
EP0677107B1 (fr) Inhibiteur de thrombine provenant de salive de protostomiens
EP1040190B1 (fr) Inhibiteurs de serine-proteinase
DE19737105A1 (de) Neue gewebsspezifische Calpaine, ihre Herstellung und Verwendung
WO2000078963A1 (fr) Inhibiteurs de la serine protease
EP0373335B1 (fr) Protéines inhibitrices des protéases du type sérine, médicaments les contenant, séquence d'ADN codant pour ces protéines et les procédés de production de ces protéines, médicament et séquences
US7258856B2 (en) Proteases from Carica having mitogenic activity and their methods of use
US7129334B2 (en) Synthetic peptide and uses for same
DE19800363A1 (de) Serin-Proteinase-Inhibitoren
JPH06321989A (ja) 新規ポリペプチド、新規ｄｎａおよび医薬組成物
DE19718248A1 (de) Neue Calpaine, ihre Herstellung und Verwendung
Ehrlich et al. Protein C: Physiologie, Biochemie und Molekularbiologie
EP0983301A2 (fr) Peptides inhibant la thrombine
DE4304731A1 (de) Thrombininhibitor aus Speichel von Protostomiern

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

17Q First examination report despatched

Effective date: 20050215

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050628